Colchicine in the treatment of scleroderma
- PMID: 926103
Item in Clipboard
Colchicine in the treatment of scleroderma
J Rheumatol.
1977 Autumn.
Abstract
We treated 10 patients with well established scleroderma with colchicine in the highest tolerated dose for one year. We could determine no clinical or laboratory improvement in any patient. Progression of disease was suggested by the development of new skin ulcers and telangiectasia, by an increase in musculoskeletal complaints, and by a significantly diminished ability to make a fist. In addition, there was deterioration of pulmonary function as demonstrated by a statistically significant fall in FEV1, and diffusing capacity. Colchicine was not of value in the treatment of scleroderma in this group of patients.
Similar articles
-
Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.Arthritis Rheum. 2006 Aug 15;55(4):598-602. doi: 10.1002/art.22099. Arthritis Rheum. 2006. PMID: 16874782
-
Long-term evaluation of colchicine in the treatment of scleroderma.J Rheumatol. 1979 Nov-Dec;6(6):705-12. J Rheumatol. 1979. PMID: 529256
-
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.Arthritis Rheum. 2006 Dec;54(12):3962-70. doi: 10.1002/art.22204. Arthritis Rheum. 2006. PMID: 17133610 Clinical Trial.
-
Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.J Rheumatol. 2008 Sep;35(9):1830-7. Epub 2008 Jul 15. J Rheumatol. 2008. PMID: 18634152 Clinical Trial.
-
Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year.Rev Rhum Engl Ed. 1998 Dec;65(12):745-50. Rev Rhum Engl Ed. 1998. PMID: 9923042 Clinical Trial.
Cited by
-
Animal models of systemic sclerosis: their utility and limitations.Open Access Rheumatol. 2014 Jul 1;6:65-81. doi: 10.2147/OARRR.S50009. eCollection 2014. Open Access Rheumatol. 2014. PMID: 27790036 Free PMC article. Review.
-
Management of oral submucous fibrosis by two different drug regimens: A comparative study.Dent Res J (Isfahan). 2013 Jul;10(4):527-32. Dent Res J (Isfahan). 2013. PMID: 24130591 Free PMC article.
-
Efficacy of colchicine in oral submucous fibrosis: A systematic review and meta-analysis.Bioinformation. 2025 May 31;21(5):1087-1092. doi: 10.6026/973206300211087. eCollection 2025. Bioinformation. 2025. PMID: 40822777 Free PMC article.
-
Scleroderma therapy: clinical overview of current trends and future perspective.Rheumatol Int. 2013 Jan;33(1):1-18. doi: 10.1007/s00296-012-2486-1. Epub 2012 Aug 3. Rheumatol Int. 2013. PMID: 23011088 Review.
-
Association of pulmonary silicosis and systemic sclerosis.BMJ Case Rep. 2015 Jan 27;2015:bcr2013202509. doi: 10.1136/bcr-2013-202509. BMJ Case Rep. 2015. PMID: 25628097 Free PMC article.